News

The company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.

STAAR Surgical President and CEO Caren Mason will be retiring December 31, and ophthalmic industry executive Thomas “Tom” G. Frinzi has been tapped as her replacement.

Company officials point out that RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.

Runa Capital-led funding will help scale the AI-powered eye pathology detection solution.

Survey of academic chairs and residency directors recognizes centers of excellence in Best Clinical Care, Best Residency, Best Research, and Best Overall Programs.

Spanish investigators found that local resection may offer better visual results and eye sparing without compromising local tumor control and survival.

Results from our recent poll indicate a mixed bag of responses from ophthalmologists.

Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.

Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.

The test is slated for further clinical development in the first quarter of 2023 and, once FDA approved, will be added to the company's catalog of ophthalmological diagnostic tools available to clinicians throughout North America.

Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.

Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.

Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.

The company is poised to roll out its eye-tracking amblyopia treatment to the U.S. market.

The American Academy of Ophthalmology has declared December as Safe Toys and Celebrations Month, highlighting how eye-safe toys can help avoid serious eye injuries.

The drug is expected to be available to eye care clinicians in the US during the second half of 2023.

According to the study, attendance improved by 9% and the return on investment totaled $11,387 over a 12-week period.

The IDMC recommended continuation of the study based upon the outcome of the futility analysis.

Harrow Health Inc. announced it has agreed to purchase the exclusive U.S. commercial rights to 5 ophthalmic drugs from Novartis AG for up to $175 million, the company announced today.

The partnership was formalized at the recent International Conference for Initiatives on Organ and Tissue Donation and Transplantation in Abu Dhabi.

The investigators explained that deficient ophthalmologic care is costly to patients, making the identification of groups not receiving adequate care of vital importance

Under the terms of the agreement, Ocular will pay Titan an upfront licensing fee with the potential for additional payments upon reaching certain milestones.

According to researcher, the treatment offers improved retinal sensitivity, visual function, and mobility.

Ophthalmologist discusses the impact of getting older on patients diagnosed with the disease.

AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.

The ocular biomarkers studied showed poor to moderate accuracy for detecting the 2 disorders.

CXL has been proven effective to treat patients with corneal ectasias.

The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with geographic atrophy secondary to AMD that addresses the underlying causes of the disease.

Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.

The Ernest E. Tschannen Eye Institute is dedicated to eye care and sight restoration through technology, pioneering research and eye care clinicians.